| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/10/2002 | US20020004032 Macrocyclic chelants for metallopharmaceuticals |
| 01/10/2002 | DE10031971A1 Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung Polymorphic forms / hydrates of N- [4- (3-chloro-4-fluoro-phenylamino) -7- (3-morpholin-4-yl-propoxy) -quinazolin-6-yl] -acrylamide dihydrochloride, processes for their preparation and to the use thereof for the preparation of medicaments with irreversible Tyrosinkinasehemmwirkung |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2585012A1 Antibodies that immunospecifically bind to blys |
| 01/10/2002 | CA2416292A1 Transgenic mice containing targeted gene disruptions |
| 01/10/2002 | CA2415123A1 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | CA2415088A1 Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists |
| 01/10/2002 | CA2414995A1 Inhibitory pas domain protein (ipas) and screening methods related to angiogenesis and tumor progression |
| 01/10/2002 | CA2414885A1 Heteropolycyclic inhibitors |
| 01/10/2002 | CA2414705A1 Thienopyrrolidinones |
| 01/10/2002 | CA2414672A1 Novel human serine-threonine kinase |
| 01/10/2002 | CA2414660A1 Use of galiella lactone |
| 01/10/2002 | CA2414650A1 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | CA2414596A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/10/2002 | CA2414468A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | CA2414461A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | CA2414446A1 Ruthenium (ii) compounds for use in the therapy of cancer |
| 01/10/2002 | CA2414355A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | CA2413802A1 Substituted-triazolopyrimidines as anticancer agents |
| 01/10/2002 | CA2413756A1 Dna encoding human serine protease d-g |
| 01/10/2002 | CA2413715A1 Grf2-binding proteins and applications thereof |
| 01/10/2002 | CA2413262A1 B7-like molecules and uses thereof |
| 01/10/2002 | CA2413245A1 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | CA2413237A1 Alteration of cell membrane for new functions |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413166A1 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | CA2413158A1 Ecm-related tumor marker |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2413002A1 Novel pyrazinone derivatives |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412845A1 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 01/10/2002 | CA2412775A1 Antibodies to human mcp-1 |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2410679A1 Secretion and trafficking molecules |
| 01/10/2002 | CA2410551A1 Heterodimeric fusion proteins |
| 01/10/2002 | CA2407910A1 Antibodies that immunospecifically bind to blys |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170591A2 Methods for identifying combinations of entities as therapeutics |
| 01/09/2002 | EP1170368A2 Immunization by inoculation of dna transcription unit |
| 01/09/2002 | EP1170018A1 Ligand-bonded complex |
| 01/09/2002 | EP1170011A1 Novel use of inhibitors of the epidermal growth factor receptor |
| 01/09/2002 | EP1170008A1 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 01/09/2002 | EP1170007A1 Remedies |
| 01/09/2002 | EP1169469A1 Human colon cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169446A2 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169444A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 01/09/2002 | EP1169443A1 REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF GENES REGULATED BY p21 |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169351A1 Polypeptides derived from endostatin exhibiting antiangiogenic activity |
| 01/09/2002 | EP1169350A2 Human obesity protein binding protein-2 homolog compositions and uses thereof |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169347A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/09/2002 | EP1169345A2 Genes associated with diseases of the kidney |
| 01/09/2002 | EP1169344A1 47 human secreted proteins |
| 01/09/2002 | EP1169336A1 Ent-steroids as selectively active estrogens |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169327A1 L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169322A1 Pyridoxal analogues for vitamin b-6 disorders |
| 01/09/2002 | EP1169320A1 Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof |
| 01/09/2002 | EP1169319A1 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| 01/09/2002 | EP1169316A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169307A1 Pyrimidine compounds with pharmaceutical activity |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169305A1 Indigoid bisindole derivatives |
| 01/09/2002 | EP1169303A2 Novel aryl-chloro-ethyl ureas |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169301A1 A topical antiandrogen for hair loss and other hyperandrogenic conditions |
| 01/09/2002 | EP1169062A2 Heat stable coated colloidal iron oxides |
| 01/09/2002 | EP1169059A1 Docetaxel in combination with rhumab her2 for the treatment of cancers |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169049A2 Treatment of myeloma bone disease with proteasomal and nf-kappa-b activity inhibitors |
| 01/09/2002 | EP1169045A2 Immunomodulating polymers |
| 01/09/2002 | EP1169044A1 Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence |
| 01/09/2002 | EP1169042A1 Dibenzo-azepine derivatives as alpha v integrin receptor antagonists |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169035A2 Anti-tumor synergetic composition |
| 01/09/2002 | EP1169025A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 01/09/2002 | EP1169021A1 Compositions and methods for treating lymphoma |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168924A1 In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens |
| 01/09/2002 | EP1168919A2 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
| 01/09/2002 | EP1168917A2 Human lung cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1076568A4 Non-invasive methods to detect prostate cancer |
| 01/09/2002 | EP0996617B1 2,4-Dithi(oxo)-pyridin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists |
| 01/09/2002 | EP0986569A4 Process for preparing etoposide |
| 01/09/2002 | CN1330715A Selectively replicating viral vectors |
| 01/09/2002 | CN1330713A Zinc finger binding domains for GNN |
| 01/09/2002 | CN1330664A Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| 01/09/2002 | CN1330660A Cycle tetrapeptide compound and their use |
| 01/09/2002 | CN1330659A Pregnane glucuronides compound |
| 01/09/2002 | CN1330654A 4,5-pyrrolo-oxindoles |
| 01/09/2002 | CN1330653A 4,5-pyrazinoxindoles as protein kinase inhibitors |
| 01/09/2002 | CN1330647A 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 |
| 01/09/2002 | CN1330642A N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |